Ectonucleotidase activities are altered in serum and platelets of l-NAME-treated rats

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 2, 2008, Pages 223-229

  Fürstenau, Cristina Ribas ^a   Trentin, Danielle da Silva ^a   Gossenheimer, Agnes Nogueira ^a   Ramos, Denise Barbosa ^a   Casali, Emerson André ^b   Barreto Chaves, Maria Luiza Morais ^c   Sarkis, João José Freitas ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ectonucleotidases; l NAME induced hypertension; Platelets; Serum

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ECTONUCLEOTIDASE; HYPOXANTHINE; N(G) NITROARGININE METHYL ESTER; NUCLEOTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FLUID INTAKE; HEART LEFT VENTRICLE; HEART WEIGHT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; HYPERTENSION; MALE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SERUM; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE;

ADENINE NUCLEOTIDES; ADENOSINE TRIPHOSPHATASES; ANIMALS; BLOOD PLATELETS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; NG-NITROARGININE METHYL ESTER; RATS; SERUM;

ANIMALIA; RATTUS;

EID: 48749127572     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.04.009     Document Type: Article

References (46)

1. World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21 (2003) 1983-1992
2. Ganong W. Review of Medical Physiology. 17th ed. (1995), Appleton & Lange, Connecticut
3. Katsumi H., Nishikawa M., and Hashida M. Development of nitric oxide donors for the treatment of cardiovascular diseases. Cardiovasc. Hematol. Agents Med. Chem. 5 (2007) 204-208
4. Moncada S., and Higgs E.A. Nitric oxide and the vascular endothelium. Handb. Exp. Pharmacol. 176 (2006) 213-254
5. Blaise G.A., Gauvin D., Gangal M., et al. Nitric oxide, cell signaling and cell death. Toxicology 208 (2005) 177-192
6. Lerman L.O., Chade A.R., Sica V., and Napoli C. Animal models of hypertension: an overview. J. Lab. Clin. Med. 146 (2005) 160-173
7. Dwyer K.M., Robson S.C., Nandurkar H.H., et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J. Clin. Invest. 113 (2004) 1440-1446
8. Kahner B.N., Shankar H., Murugappan S., et al. Nucleotide receptor signaling in platelets. J. Thromb. Haemost. 4 (2006) 2317-2326
9. Coade S.B., and Pearson J.D. Metabolism of adenine nucleotides in human blood. Circ. Res. 65 (1989) 531-537
10. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology and pharmacology. Am. J. Cardiol. 79 (1997) 2-10
11. El-Omar M.M., Islam N., Broekman M.J., et al. The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery disease. Thromb. Res. 116 (2005) 199-206
12. Zimmermann H., and Pearson J. Extracellular metabolism of nucleotides and adenosine in the cardiovascular system. In: Burnstock G., Dobson J.G., Liang B.T., and Linden J. (Eds). Cardiovascular biology of purines (1998), Kluwer Academic Publishers, Dordrecht 342-358
13. Marcus A.J., Broekman M.J., Drosopoulos J.H., et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin. Thromb. Hemost. 31 (2005) 234-245
14. Zimmermann H., Miras-Portugal M.T., and Pintor J. Ectonucleotidases: some recent developments and a note on nomenclature. Drug. Dev. Res. 52 (2001) 44-56
15. Agteresch H.J., Dagnelie P.C., van der Berg J.W., and Wilson J.L. Adenosine triphosphate: established and potential clinical applications. Drugs 58 (1999) 211-252
16. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J. Pharmacol. Exp. Ther. 305 (2003) 09-16
17. Pravenec M., Kunes J., Zicha J., et al. Platelet aggregation in spontaneous hypertension: genetic determination and correlation analysis. J. Hypertens. 10 (1992) 1453-1456
18. Erne P., Resink T.J., Burgisser E., et al. Platelets and hypertension. J. Cardiovasc. Pharmacol. 7 (1985) 103-108
19. Oses J.P., Cardoso C.M., Germano R.A., et al. Soluble NTPDase: an additional system of nucleotide hydrolysis in rat blood serum. Life Sciences 74 (2004) 3275-3284
20. Sakura H., Nagashima S., Nakahima A., and Maeda M. Characterization of fetal serum 5′-nucleotide phosphodiesterase: a novel function as a platelet aggregation inhibitor in fetal circulation. Thromb. Res. 91 (1998) 83-89
21. Frassetto S.S., Dias R.D., and Sarkis J.J.F. Characterization of an ATP diphosphohydrolase activity (EC 3.6.1.5) in rat blood platelets. Mol. Cell. Biochem. 129 (1993) 47-55
22. Fürstenau C.R., Trentin D.S., Barreto-Chaves M.L.M., and Sarkis J.J.F. Ecto-nucleotide pyrophosphatase/phosphodiesterase as part of a multiple system for nucleotide hydrolysis by platelets from rats: kinetic characterization and biochemical properties. Platelets 17 (2006) 84-91
23. Duarte M.M.F., Loro V.L., Rocha J.B.T., et al. Enzymes that hydrolyze adenine nucleotides of patients with hypercholesterolemia and inflammatory processes. FEBS J. 274 (2007) 2707-2714
24. Zanfolin M., Faro M., Araújo E.G., et al. Protective effects of BAY 41-2272 (sGC Stimulator) on hypertension, heart and cardiomyocyte hypertrophy induced by chronic l-NAME treatment in rats. J. Cardiovasc. Pharmacol. 47 (2006) 391-395
25. Kawagushi H., Sano H., and Kitabatake A. Increased mRNA expression of renin-angiotensin system in hyperthrophied rat heart. In: Sharma, et al. (Ed). Adaptation Biology and Medicine (1997), Narosa Publishing House, New Delhi
26. Hantgan R.R. A study of the kinetic ADP-triggered platelet shape change. Blood 64 (1984) 806-906
27. Yegutkin G.G. Kinetic analysis of enzymatic hydrolysis of ATP in human and rat blood serum. Biochem.-Moscow 62 (1997) 724-728
28. Yegutkin G.G., Samburski S.S., and Jalkanen S. Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions. FASEB J. 17 (2003) 1328-1330
29. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
30. 2+-ATPase activity. Anal. Biochem. 157 (1986) 375-380
31. Voelter W., Zech K., Arnold P., and Ludwig G. Determination of selected pyrimidines, purines and their metabolites in serum and urine by reversed-phase ion-pair chromatography. J. Chromatogr. 199 (1980) 345-354
32. Francischetti I.M.B., Ribeiro J.M.C., Champagne D., et al. Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus. J. Biol. Chem. 275 (2000) 12639-12650
33. Duhamel T.A., Xu Y.J., Arneja A.S., et al. Targeting platelets for prevention and treatment of cardiovascular disease. Expert. Opin. Ther. Targets 11 (2007) 1523-1533
34. Rossoni L.V., dos Santos L., Barker L.A., and Vassalo D.V. Ouabain changes arterial blood pressure and vascular reactivity to phenylephrine in l-NAME-induced hypertension. J. Cardiovasc. Pharmacol. 41 (2003) 105-116
35. Kalayci R., Kaya M., Ahishali B., et al. Long-term l-NAME treatment pontentiates the blood-brain barrier disruption during pentylenetetrazole-induced seizures in rats. Life Sci. 30 (2006) 16-20
36. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
37. Balbinott A.W., Irigoyen M.C., Brasileiro-Santos M.S., et al. Dose-dependent autonomic dysfunction in chronic l-NAME hypertensive diabetic rats. J. Cardiovasc. Pharmacol. 46 (2005) 563-569
38. Doggrell S.A., and Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc. Res. 39 (1998) 89-105
39. Shapiro L.M., and Sugden P.H. Left ventricular hypertrophy. In: Julian D.G., Camm A.J., Fox K.M., et al. (Eds). Diseases of the heart. second ed. (1996), Saunders, London
40. Dubyak G.R., and El-Moatassim C. Signal transduction via P2 purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. 265 (1993) 577-606
41. Robson S.C., Sévigny J., and Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purin. Signal. 2 (2006) 409-430
42. Sévigny J., Sundberg C., Braun N., et al. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase 2 have implications for thromboregulation. Blood 99 (2002) 2801-2809
43. Kinugawa T., Ogino K., Osaki S., et al. Altered purine nucleotide degradation during exercise in patients with essential hypertension. Metabolism 6 (2001) 646-650
44. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88 (2001) 756-762
45. Moncada S., and Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147 (2006) 193-201
46. Meirelles L.R., Mendes-Ribeiro A.C., Santoro M.M., et al. Inhibitory effects of endogenous l-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension. Clin. Exp. Pharmacol. Physiol. 34 (2007) 1267-1271